Advertisement
Screener

KODIAK SCIENCES INC. (KOD) Increase (Decrease) in Other Operating Liabilities

2.8 / 5 stars · 68/120 Roast Me

KODIAK SCIENCES INC. Increase (Decrease) in Other Operating Liabilities

KODIAK SCIENCES INC. (KOD) reported Increase (Decrease) in Other Operating Liabilities of $0 for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-01.

Discontinued › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInOtherOperatingLiabilities · last filed 2021-03-01

  • KODIAK SCIENCES INC. increase (decrease) in other operating liabilities for the quarter ending 2018-12-31 was -$2.00K, a 113.33% decline year-over-year.
  • KODIAK SCIENCES INC. increase (decrease) in other operating liabilities for the quarter ending 2018-09-30 was $11.00K.
  • KODIAK SCIENCES INC. increase (decrease) in other operating liabilities for the quarter ending 2018-06-30 was $14.00K.
  • KODIAK SCIENCES INC. increase (decrease) in other operating liabilities for the quarter ending 2018-03-31 was $8.00K.
  • KODIAK SCIENCES INC. increase (decrease) in other operating liabilities for fiscal 2020 was $0.00.
  • KODIAK SCIENCES INC. increase (decrease) in other operating liabilities for fiscal 2019 was $0.00, a 100.00% decline from fiscal 2018.
  • KODIAK SCIENCES INC. increase (decrease) in other operating liabilities for fiscal 2018 was $31.00K, a 35.42% decline from fiscal 2017.
  • KODIAK SCIENCES INC. increase (decrease) in other operating liabilities for fiscal 2017 was $48.00K.
Period endIncrease (Decrease) in Other Operating Liabilities 3 monthIncrease (Decrease) in Other Operating Liabilities 6 monthIncrease (Decrease) in Other Operating Liabilities 9 monthIncrease (Decrease) in Other Operating Liabilities 12 month
2020-12-31$0.00
10-K · filed 2021-03-01
2019-12-31$0.00
10-K · filed 2021-03-01
2018-12-31-$2.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01
$9.00K
derived: sum of 2 quarters · filed 2021-03-01
$23.00K
derived: sum of 3 quarters · filed 2021-03-01
$31.00K
10-K · filed 2021-03-01
2018-09-30$11.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12
$25.00K
derived: sum of 2 quarters · filed 2019-11-12
$33.00K
10-Q · filed 2019-11-12
$48.00K
derived: sum of 4 quarters · filed 2020-03-16
2018-06-30$14.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14
$22.00K
10-Q · filed 2019-08-14
$37.00K
derived: sum of 3 quarters · filed 2020-03-16
2018-03-31$8.00K
10-Q · filed 2019-05-15
$23.00K
derived: sum of 2 quarters · filed 2020-03-16
2017-12-31$15.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16
$48.00K
10-K · filed 2020-03-16
2017-09-30$33.00K
10-Q · filed 2018-11-16
2016-12-31-$14.00K
10-K · filed 2019-03-27

Similar stocks

Stock NameCountryMarket CapPE Ratio
RECURSION PHARMACEUTICALS, INC. (RXRX)United States$2.080B-3.78
ADMA BIOLOGICS, INC. (ADMA)United States$2.131B11.16
Vericel Corp (VCEL)United States$2.011B93.97
BIOCRYST PHARMACEUTICALS INC (BCRX)United States$2.175B-6.63
Greenland Mines Ltd (GRML)United States$2.362B
Vir Biotechnology, Inc. (VIR)United States$1.814B-6.85
NOVAVAX INC (NVAX)United States$1.748B-6.26
Hemab Therapeutics Holdings, Inc. (COAG)United States$1.672B
Beam Therapeutics Inc. (BEAM)United States$2.549B-41.51
Immunocore Holdings plc (IMCR)$1.613B-90.43